Article Text

Download PDFPDF
Is Neoadjuvant Chemotherapy Followed by Radical Surgery More Effective Than Radiation Therapy for Stage IIB Cervical Cancer?
  1. Dae Woo Lee, MD*,
  2. Keun Ho Lee, MD, PhD,
  3. Jung Won Lee, MD,§,
  4. Sung Taek Park, MD, PhD,
  5. Jong Sup Park, MD, PhD and
  6. Hae Nam Lee, MD, PhD*
  1. *Department of Obstetrics and Gynecology, Bucheon St. Mary’s Hospital, College of Medicine,
  2. Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, College of Medicine,
  3. Department of Obstetrics and Gynecology, Yeouido St. Mary’s Hospital, College of Medicine,
  4. §Department of Obstetrics and Gynecology, Incheon St. Mary’s Hospital, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea; and
  5. Department of Obstetrics and Gynecology, Hallym University Gangnam Sungsim Hospital, College of Medicine, Hallym University of Korea, Seoul, Republic of Korea.
  1. Address correspondence and reprint requests to Hae Nam Lee, MD, PhD, Bucheon St. Mary’s Hospital, Sosa-dong, Wonmi-gu, Bucheon-si, Gyeonggi-do, Korea, 420-717. E-mail: leehaenam{at}catholic.ac.kr.

Abstract

Objective The primary objective of the study was to compare the survival rate of patients who had received neoadjuvant chemotherapy with that of patients who had received radiation therapy for stage IIB cervical cancer. The secondary objective was to analyze the effect of neoadjuvant chemotherapy on pathological prognostic factors.

Materials and Methods We retrospectively reviewed the medical records of patients who had received therapy for stage IIB cervical cancer. Based on the primary therapy, 192 patients were divided into 2 groups; patients in the neoadjuvant chemotherapy group (n =103) underwent a type III radical hysterectomy after completion of the neoadjuvant chemotherapy. Patients in the other group (n = 89) were treated with radiation alone or a combination of chemotherapy and radiotherapy.

Results After neoadjuvant chemotherapy, the level of squamous cell carcinoma antigen, tumor size, lymph node involvement, and parametrium involvement were significantly decreased. However, 90.3% of the patients who had received neoadjuvant chemotherapy needed to have adjuvant therapy after radical surgery because of poor pathological prognostic factors. The rate of disease-free survival did not differ significantly between the 2 groups. However, the overall survival rate was significantly lower in the neoadjuvant chemotherapy group for patients who were 60 years or older (P = 0.03). The rates of disease-free survival and overall survival for patients who had a good (complete or partial) response to the neoadjuvant chemotherapy were not significantly higher than the rates for patients in the radiation therapy group.

Conclusions Although neoadjuvant chemotherapy improved pathological prognostic factors in patients with stage IIB cervical cancer, it was not sufficiently effective to decrease adjuvant therapy. Neoadjuvant chemotherapy also did not improve the rate of patient survival compared to the rate of patient survival in the radiation therapy group.

  • Cervical cancer IIB
  • Neoadjuvant chemotherapy
  • Survival

Statistics from Altmetric.com

Footnotes

  • No funding support was received for this work.

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.